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Abstract
Receptor tyrosine kinases (RTKs) activate multiple downstream cytosolic tyrosine kinases following ligand stimulation. SRC
family kinases (SFKs), which are recruited to activated RTKs through SH2 domain interactions with RTK autophosphorylation
sites, are targets of many subfamilies of RTKs. To date, there has not been a systematic analysis of the downstream
substrates of such receptor-activated SFKs. Here, we conducted quantitative mass spectrometry utilizing stable isotope
labeling (SILAC) analysis to profile candidate SRC-substrates induced by the CSF-1R tyrosine kinase by comparing the
phosphotyrosine-containing peptides from cells expressing either CSF-1R or a mutant form of this RTK that is unable to bind
to SFKs. This analysis identified previously uncharacterized changes in tyrosine phosphorylation induced by CSF-1R in
mammary epithelial cells as well as a set of candidate substrates dependent on SRC recruitment to CSF-1R. Many of these
candidates may be direct SRC targets as the amino acids flanking the phosphorylation sites in these proteins are similar to
known SRC kinase phosphorylation motifs. The putative SRC-dependent proteins include known SRC substrates as well as
previously unrecognized SRC targets. The collection of substrates includes proteins involved in multiple cellular processes
including cell-cell adhesion, endocytosis, and signal transduction. Analyses of phosphoproteomic data from breast and lung
cancer patient samples identified a subset of the SRC-dependent phosphorylation sites as being strongly correlated with
SRC activation, which represent candidate markers of SRC activation downstream of receptor tyrosine kinases in human
tumors. In summary, our data reveal quantitative site-specific changes in tyrosine phosphorylation induced by CSF-1R
activation in epithelial cells and identify many candidate SRC-dependent substrates phosphorylated downstream of an RTK.
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Introduction
Growth factors and their cognate receptor tyrosine kinases
(RTK) are key regulators of tumor cell initiation and progression
[1]. Growth factor binding and subsequent RTK auto-phosphor-
ylation lead to the activation of pathways that regulate cell
proliferation, survival, growth, adhesion and motility. Inappropri-
ate RTK activation can drive tumor cell growth, survival, invasion
and metastasis. RTKs like epidermal growth factor receptor
(EGFR) and epidermal growth factor receptor 2 (Her2/ERBB2)
are overexpressed or activated in a variety of human cancers [2].
In non-small cell lung cancers (NSCLC), activating EGFR
mutations are found in 10–15% of Caucasian and 30–40% Asian
patients [3,4]. ERBB2, as a further example, is upregulated by
gene amplification in 15–30% of invasive mammary ductal
cancers [1]. RTKs are known to activate several downstream
tyrosine kinases, including members of the SRC, ABL, and JAK
kinase families. These cytosolic kinases make a significant
contribution to the dramatic increase in tyrosine phosphorylation
induced by RTKs. It has been difficult to define the precise subset
of proteins targeted by any individual tyrosine kinase that is a
component of these kinase signaling cascades due to the overlap in
substrates phosphorylated by activated RTKs and non-receptor
tyrosine kinases. Previous studies have utilized activated mutant
variants of non-receptor tyrosine kinases like SRC to identify
downstream substrates of this kinase subfamily; however, these
overexpressed, constitutively active mutants likely display promis-
cuous activities that do not necessarily reflect the substrates of the
endogenous protein when activated by an upstream RTK.
SRC and other SRC family kinases (SFKs) are activated
downstream of many different RTKs [5]. SRC activity is critical
for several phenotypic events induced by RTK activation
including DNA synthesis, cytoskeletal reorganization and disrup-
tion of cell-cell adhesion [6,7,8]. In human tumors, RTK
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13587activation of SFKs may contribute to tumor progression and lead
to more aggressive tumor phenotypes [9]. Dominant negative
SRC mutants, pharmacological inhibition of SRC kinase activity,
and SRC-specific docking site RTK mutants have been used to
address the specific role of SRC in RTK signal transduction [10].
Studies in breast cancer models using these methods have
demonstrated that inhibition of SRC kinase activity suppresses
phenotypic effects induced by the overexpression or activation of
RTKs like EGFR and ERBB2, e.g. anchorage-independent
growth, motility and survival [10,11,12,13]. Therefore, RTK-
induced SRC activity drives aspects of RTK signaling important
in tumor progression, and the identification of RTK-induced SRC
substrates will offer further insight into the role of SRC in
tumorigenesis.
We previously demonstrated [8] that Src activation regulates a
subset of phenotypic alterations induced by the colony stimulating
factor 1 receptor tyrosine kinase (CSF-1R), which has been
implicated in the progression of multiple types of carcinoma
including breast cancer [14,15,16,17,18,19,20]. SRC activity was
found to be critical for CSF-1R-induced disruption of cell-cell
adhesion of MCF-10A cells, immortalized, non-transformed
mammary epithelial cells [8]. These alterations are associated
with loss of plasma membrane association of E-cadherin, a key
regulator of epithelial intercellular adhesion. The CSF-1R tyrosine
phosphorylation site that binds to SRC and other SFKs, Y561,
was found to be critical for disruption of cell-cell adhesion [8,21].
Expression of a dominant-negative mutant of SRC (c-SRC
K295R) or pharmacological inhibition of SRC kinase activity in
the presence of CSF-1R activation preserves cell-cell adhesion,
providing additional evidence that SRC activity and phosphory-
lation of SRC substrates are involved in the disruption observed
[8].
Few studies have examined the specific set of SRC substrates
phosphorylated after RTK activation [10,22]. A recent mass
spectrometry (MS) analysis by Amanchy and colleagues identified
43 candidate SRC substrates downstream of platelet-derived
growth factor (PDGF) receptor in fibroblasts using SU6656, a
pharmacological inhibitor of SRC kinase activity [22]. While this
work identified candidate substrates of endogenous SRC, all
cellular SRC family kinases were inhibited by this inhibitor, so this
analysis did not distinguish substrates that are directly downstream
of PDGFR activation from those regulated by adhesion receptors
and other cellular processes. Several MS analyses have identified
proteins that display increased tyrosine phosphorylation in cells
overexpressing wild-type SRC or an activated mutant variant
[23,24,25,26]. However, the relevance of these targets in human
tumors is not clear, as SRC is not frequently mutated or
overexpressed in breast cancers, and it is more likely activated in
breast carcinomas by an upstream activated RTK or another
receptor known to couple to SRC [5,10,11,13,27].
Using quantitative MS analysis, we examined CSF-1R-induced
tyrosine phosphorylation using quantitative PhosphoScanH anal-
ysis. PhosphoScanH analysis is an MS approach that utilizes
immunoaffinity purification of tyrosine phosphorylated peptides
prior to MS analysis to enrich their representation in the sample
[23]. We profiled site-specific changes in tyrosine phosphorylation
induced by activated CSF-1R and activated CSF-1R defective for
the recruitment of SFKs in MCF-10A cells. To do this, we utilized
a previously described constitutively active variant of CSF-1R
(CA-CSF-1R) and CA-CSF-1R with a tyrosine to phenylalanine
substitution at Y561 (CA-CSF-1R Y561F), the recruitment site for
SRC and SFKs [8]. This phosphotyrosine proteomic MS analysis
of parental MCF-10As and cells expressing the two CSF-1R
variants allowed us to characterize CSF-1R-induced tyrosine
phosphorylation events and to distinguish Y561-independent and
Y561-dependent phosphorylation events stimulated by the acti-
vated CSF-1R. The Y561-dependent substrates revealed a set of
putative SRC substrates and subsequent bioinformatics analyses of
these targets in human tumor datasets identified potential
biomarkers of SRC activation in human tumors.
Results
Quantitative MS analysis
To systematically profile changes in tyrosine phosphorylation
downstream of CSF-1R activation and identify candidate SRC
substrates, we conducted quantitative liquid chromatography and
tandem MS (LC-MS/MS) analysis using metabolic labeling with
stable isotopes (SILAC) together with phosphotyrosine proteome
analysis using samples derived from MCF-10A cells expressing
either CA-CSF-1R or CA-CSF-1R Y561F [23]. For quantitative
analysis using SILAC, one experimental sample is labeled with
‘‘heavy’’ amino acids, while the other sample is grown in the
presence of ‘‘light’’ amino acids. In this study, CA-CSF-1R-
expressing MCF-10A cells were labeled with ‘‘heavy’’
13C6-
15N2-
L-lysine and
13C6-
15N4-L-arginine. Cells expressing CA-CSF-1R
Y561F and parental MCF-10A cells were labeled with the
corresponding ‘‘light’’ isotopic variants of the same amino acids
(Figure 1A). Naturally occurring amino acid isotopic variants were
eliminated from the serum supplementing the growth medium by
dialysis, and cells were passaged a minimum of five times in the
labeling medium to ensure complete incorporation of the labeled
amino acid. Before harvesting for phosphotyrosine proteome
analysis, the cells were cultured in the absence of EGF, as EGF-
starvation leads to dominant CSF-1R signaling in MCF-10A cells
overexpressing the CSF-1R [8]. Samples were mixed in a 1:1
‘‘heavy/light’’ ratio, proteolytically digested, and subjected to
phosphotyrosine immunoprecipitation prior to LC-MS/MS.
We quantitatively assessed the tyrosine phosphorylation of 275
peptides in the comparison of CA-CSF-1R MCF-10A cells to
parental MCF-10A cells (Table S1), and 324 peptides in the
comparison of CA-CSF-1R MCF-10A cells to CA-CSF-1R Y561F
MCF-10A cells (Table S2). The fold differences in tyrosine
phosphorylated peptides were calculated by determining the ratio
of tyrosine phosphorylated peptides detected in each of the cell
pairs e.g., CA-CSF-1R vs. parental MCF-10A cells or CA-CSF-
1R vs. CA-CSF-1R Y561F cells (Figure 1A). Figure 1B illustrates
the distribution of the identified phosphopeptides for each
comparison (CA-CSF-1R/MCF-10A; CA-CSF-1R/CA-CSF-1R
Y561F) relative to the fold change differences in tyrosine
phosphorylation.
CSF-1R induced changes in phosphorylation
To guide our assignment of the threshold for significant fold
changes phosphorylation, we first graphed the distribution of the
non-phosphorylated peptides present in the immunoprecipitated
samples and determined the mean of the quantitative fold change
values. We assumed data normality based on these distributions;
therefore, fold change values greater than two deviations from the
mean are considered 95% likely to represent significant differences
in tyrosine phosphorylation. Each comparison had a different
mean value for the non-phosphopeptide distribution; however, the
same statistical threshold was applied to both comparisons. For the
CA-CSF-1R/parental MCF-10A comparison, fold change ratios
.1.94 were defined as an upregulation in the levels of tyrosine
phosphorylation, ratios 0.64–1.94 as unchanged, and ratios ,0.64
as a downregulation of tyrosine phosphorylation.
RTK-Induced SRC substrates
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threshold level in cells expressing CA-CSF-1R relative to parental
MCF-10A cells and were defined as ‘‘CSF-1R-induced’’ (Table 1).
The threshold value (ratio .1.94) used in this analysis was based
on a statistical analysis comparing non-phosphorylated and
phosphorylated peptides detected in the screen (see Materials
Figure 1. Quantitative MS profiles CSF-1R-induced and SRC-dependent changes in tyrosine phosphorylation in MCF-10A cells. A)
Schematic of experimental design showing the CSF-1R constitutively active mutants used in MCF-10A cells to profile changes in tyrosine phosphorylation
and the protocol followed for quantitative MS analysis B) Graph of data from quantitative MS analysis depicting the distribution of peptides relative to the
fold change in tyrosine phosphorylation levels. Blue: CA-CSF-1R vs. parental MCF-10A; Red: CA-CSF-1R vs. CA-CSF-1R Y561F MCF-10A.
doi:10.1371/journal.pone.0013587.g001
RTK-Induced SRC substrates
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Protein Name UniProt# NCBI Site Fold change* (CA-CSF-1R/MCF-10A) Fold change* (CA-CSF-1R/Y561F) Src regulation
Transferrin receptor P02786 Y20 313.67 -
APLP2 Q06481 Y750 73.37 -
D-Prohibitin Q99623 Y248 .55.42 -
PAR3 Q8TEW0 Y489 .34.42 -
PKM2 P14618-2 Y105 29.01 -
PIK3R1 P27986 Y470 .24.59 -
PIK3R1 P27986 Y607 .22.45 -
PAR3 Q8TEW0 Y719 19.88 -
LAPTM4A Q15012 Y230 .18.02 -
TAOK1 Q7L7X3 Y309 .17.57 -
PIK3R2 O00459 Y577 .13.95 -
Beta-adaptin P63010 Y277 .12.57 -
UBXD8 Q96CS3 Y79 .12.42 -
UQCRC2 P22695 Y207 .10.13 -
HSP90-beta P08238 Y483 9.54 -
CCT-theta P50990 Y29 9.4 -
Syndecan-4 P31431 Y197 6.8 -
CSF-1R P07333 Y556 .5.68 -
CDC2 P06493 T14 4.18 -
EphA2 P29317 T593 3.58;3.58 -
CDC2 P06493 Y19 3.36 -
IRS2 Q9Y4H2 Y598 3.27 -
CASKIN-2 Q8WXE0 Y253 3.21 -
Desmoglein Q14126 Y1013 2.06 -
EphB4 P54760 Y774 2.03;2.03;2.03 1.75;1.75 Src-dependent
FLJ20625 Q9NWT0 Y40 .19.60 2.06 Src-dependent
EphA2 P29317 Y575 3.28 2.11 Src-dependent
Beta-adaptin P63010 Y276 .11.05;26.66 2.12 Src-dependent
KIAA0323 O15037 Y456 .14.07;150.39;105.93 2.22;1.98;1.98;1.7 Src-dependent
Intersectin 2 Q9NZM3 Y552 51.99 2.73;2.73 Src-dependent
ACK Q07912 Y518 2.29 3.45 Src-dependent
Hrs O14964 Y216 148.61 3.51;3.5 Src-dependent
ZDHHC7 Q9NXF8 Y130 .50.78;173.17 4.05;3.99;3.98 Src-dependent
TJAP1 Q5JTD0 Y352 .88.49 4.31 Src-dependent
Hrs O14964 Y334 .34.54;229.48 4.49 Src-dependent
Hrs O14964 Y132 .296.57;1823.09;28.34;8.78 5.06;3.12;3.12;3.11;3.11;2.63;2.63 Src-dependent
p120 catenin O60716 Y904 3.27;3.27 5.31;5.31 Src-dependent
CSF-1R P07333 Y561 .37.45 .16.44 Src-dependent
STAT3 P40763-2 Y704 4.85;4.45;4.45 0.73;0.72;0.72 Src-independent
Plakophilin 3 Q9Y446 Y176 2.37;2.37 0.74 Src-independent
RPS10 P46783 Y12 10.35 0.74;0.74 Src-independent
STAT3 P40763 Y705 4.76;4.76;4.64;4.64 0.77;0.77 Src-independent
Insulin Receptor P06213 Y1189 2.41 0.84;0.84;0.73 Src-independent
Talin 1 Q9Y490 Y70 31.66 0.84 Src-independent
ACLY P53396 Y1073 .26.05;.11.93 0.9;0.9 Src-independent
SHB Q15464 Y246 2.78 0.93 Src-independent
LDLR P01130 Y845 61.43;32.64 1;1 Src-independent
CSF-1R P07333 Y809 .45.71;.20.07;1292.56;10.6 1.01;1.01 Src-independent
EphA2 P29317 Y588 4.61 1.07 Src-independent
SHB Q15464 Y268 2.91;2.91 1.09;1.09 Src-independent
RTK-Induced SRC substrates
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Calmodulin P62158 Y99 127.33;70.6 1.11;1.11;0.93;0.93 Src-independent
PTTG1IP P53801 Y174 .30.11;17.83 1.15;1.11;1.11 Src-independent
EphA2 P29317 Y772 3.79;3.32;3.32 1.16;1.16;1.09;1.09 Src-independent
Integrin beta-4 P16144 Y1207 2.33;2.33;1.39;1.39 1.18 Src-independent
GSTP1 P09211 Y7 35.59 1.19;1.19 Src-independent
eEF1A-2 Q05639 Y29 3.45 0.65;0.65 Src-independent
PKC, Delta Q05655 Y374 .9.84 0.65 Src-independent
RPS27 P42677 Y31 7.36 0.66;0.66 Src-independent
CDC2 P06493 T14, Y15 5.41;5.27 0.67;0.58 Src-independent
Vimentin P08670 Y53 2.15 0.68 Src-independent
PIK3R1 P27986 Y467 6.15 0.68;0.64;0.64 Src-independent
Annexin A2 P07355 Y29 12.46;5.27;5.27 0.69;0.69 Src-independent
KIAA1217 Q5T5P2 Y244 3.08;3.07 0.7;0.7 Src-independent
PIN4 Q9Y237 Y122 .21.65 0.75;0.68;0.68 Src-independent
CSF-1R P07333 Y699 .8.52;.38.88;.32.34;.13.82 0.76;0.74;0.73;0.68;0.66;0.66;0.66;
0.62;0.56;0.56
Src-independent
CSF-1R P07333 Y923 .133.30 0.8;0.63 Src-independent
Ack Q07912 Y857 4.37 1.13; 1.01; 1.01 Src-independent
EphA2 P29317 Y588, Y594 4.53;3.66 1.16; 0.62; 0.62 Src-independent
CSF-1R P07333 Y873 .56.43;.38.15 1.3; 1.3; 1.21 Src-independent
Caveolin 1 Q03135 Y14 3.53;2.92;2.74 0.67;0.57;0.53 Src-inhibited
SLC20A1 Q8WUM9 Y388 .13.04 0.25 Src-inhibited
HGK O95819 Y1227 .15.71 0.28;0.28 Src-inhibited
GAB1 Q13480 Y659 16.82 0.31 Src-inhibited
ERK2 P28482 T184, Y186 56.77 0.31;0.31 Src-inhibited
PTRF Q6NZI2 Y308 6.84;6.13;0.96;0.94 0.35;0.35;0.34;0.28;0.28 Src-inhibited
Annexin A1 P04083 Y38 19.83 0.42;0.42 Src-inhibited
H2B2E Q16778 Y43 .31.63;1152.72 0.43;0.42;0.42 Src-inhibited
Plakophilin 3 Q9Y446 Y84 67.23;57.48 0.43;0.43;0.42;0.42 Src-inhibited
ARP2/3 Subunit 3 O15145 Y46 .9.76 0.44 Src-inhibited
PDLIM5 Q96HC4 Y251 5.23 0.49 Src-inhibited
UrdPase 1 Q16831 Y35 16.85 0.49 Src-inhibited
p120 catenin O60716 Y96 2.33 0.5 Src-inhibited
SHC1 P29353 Y427 5.87;5.87;5.53;5.53 0.51 Src-inhibited
FAM62A Q9BSJ8 Y822 7.99 0.51 Src-inhibited
ERK1 P27361 Y204 27.99 0.52 Src-inhibited
Annexin A2 P07355 Y315 236.05 0.52;0.52 Src-inhibited
CDK3 Q00526 Y15 7.46;4.62;4.61 0.53;0.53;0.43;0.21;0.21 Src-inhibited
Annexin A2 P07355 Y237 11.78;11.75;10.71 0.53;0.53;0.47 Src-inhibited
ERK2 P28482 Y186 35.57;18.11 0.53;0.53;0.47 Src-inhibited
Enolase 1 P06733 Y188 2.46 0.54 Src-inhibited
Annexin A2 P07355 Y23 3.3;3.3;2.96 0.56;0.56;0.56;0.56;0.55;0.55 Src-inhibited
SLC38A2 Q9HAV3 Y41 21.5 0.56;0.56 Src-inhibited
PIK3R1 P27986 Y580 .56.64;79.89;36.8;36.73 0.57;0.57;0.57;0.56;0.56;
0.54;0.54;0.52;0.51;0.51
Src-inhibited
DLG1 Q12959 Y760 .11.65 0.59;0.51 Src-inhibited
DLG3 Q92796 Y673 .12.59;128.61 0.59;0.59 Src-inhibited
VASP P50552 Y38 109.16 0.59 Src-inhibited
LDH-A P00338 Y238 18.81 0.6;0.6 Src-inhibited
Vimentin P08670 Y61 2.01 0.61 Src-inhibited
Table 1. Cont.
RTK-Induced SRC substrates
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tyrosine phosphorylation in CA-CSF-1R cells and were classified
as ‘‘CSF-1R downregulated’’. Forty-five tyrosine residues on 36
proteins exhibited no change in the level of tyrosine phosphory-
lation upon CSF-1R activation and were labeled as ‘‘basally
phosphorylated’’ and are likely substrates of kinases basally active
in MCF-10A cells (Table S3).
An additional 38 tyrosine sites on 36 proteins were found to be
phosphorylated in the CA-CSF-1R vs. CA-CSF-1R Y561F
analysis, but not detected in the CA-CSF-1R vs. parental MCF-
10A analysis. These sites were denoted ‘‘CSF-1R induced*’’
(Table 2). It remains a possibility that these sites are not CSF-1R
induced, but were undetectable in the parental MCF-10As from
the CA-CSF-1R vs. MCF-10A MS analysis. However, these sites
were denoted as CSF-1R-induced* to distinguish them as qualified
CSF-1R regulated sites (Table 2). Where these phosphorylated
tyrosine residues are included in later comparative analyses they
are clearly distinguished. Inclusion of these sites adds 24 CSF-1R
induced* proteins (twelve proteins had other tyrosine sites that
were unambiguously CSF-1R induced). Further validation will be
necessary to determine whether this subset of proteins is regulated
by CSF-1R activation. Overall, we identified 98 proteins with
either CSF-1R-induced (74 proteins) or CSF-1R induced* (24
proteins) tyrosine phosphorylation.
As expected, CSF-1R activation in parental MCF-10A cells
induced a strong increase in tyrosine phosphorylation. Proteins
previously shown to be tyrosine phosphorylated following CSF-1R
activation were detected in our analysis (Table 3), thus validating
this approach for identification of CSF-1R substrates. These
included STAT3, PKCd, vimentin, SHC1, annexin A1, multiple
isoforms of PI3K p85-alpha, ERK1, ERK2, and tyrosine residues
on the CSF-1R (Y556, Y561, Y699, Y809, Y873, Y923)
[28,29,30]. Similarly, the CSF-1R-induced* set of proteins
included STAT5A, YES, PYK2 and p38-alpha, which are known
to be phosphorylated downstream of CSF-1R (Table 1).
GeneGOH enrichment analysis of the CSF-1R-induced and
CSF-1R-induced* protein set revealed that CSF-1R induces
phosphorylation of proteins associated with cellular processes
including cell adhesion, developmental pathways, translation
initiation, cell cycle regulation, and cytoskeletal dynamics
(Figure 2A). Interestingly, CSF-1R activation stimulates phos-
phorylation of proteins involved in immune and inflammation
pathways e.g., interleukin (IL)-6 and IL-2 signaling and neutrophil
activation. Phosphorylation of these targets in MCF-10A cells may
reflect the conserved function of CSF-1R in the regulation of
monocyte cell differentiation and survival. Proteins with CSF-1R-
induced tyrosine phosphorylation that contribute to the enriched
biological processes are listed in Table S4. We also analyzed the
CSF-1R-induced and CSF-1R-induced* proteins for significant
association with disease and found a statistically significant
enrichment for proteins involved in tumor metastasis and
progression (Figure 2A, Table S4).
Comparative phosphoproteomics – EGFR and ERBB2-
induced tyrosine phosphorylation
MCF-10A cells over-expressing CA-CSF-1R are able to
proliferate and survive in the absence of EGF, suggesting that
CSF-1R and EGFR activate redundant signaling pathways to
some degree [8]. The quantitative MS data show that under EGF-
deficient experimental conditions phosphorylation of EGFR on
Y1172 was equivalent in parental MCF-10As and CA-CSF-1R
MCF-10As (Table S1). This data indicates that CSF-1R activation
does not influence EGFR directly, but independently activates
downstream pathways that promote proliferation and survival.
To identify phosphorylated targets common to CSF-1R and
other growth factor receptors, we compared our dataset with other
available phosphoproteomic datasets. Heibeck and colleagues
utilized phosphotyrosine peptide immunoprecipitation and high
sensitivity capillary LC-MS/MS to identify 481 basal and EGF-
induced tyrosine phosphorylation sites from 285 proteins in a non-
transformed human mammary epithelial cell (HMEC) line [31].
From the 98 proteins that showed CSF-1R-induced or CSF-1R-
induced* tyrosine phosphorylation (Table 1), there was a 51%
(50/98) overlap with EGFR-induced phosphorylated proteins in
HMECs (Figure 2B, Table S5). A number of the overlapping
proteins (ERK1, ERK2, IRS2, GAB1, SHB, SHC and PI3K p85-
alpha) are key signaling intermediates for multiple signaling
pathways. The CSF-1R and EGFR pathways also overlap in their
regulation of cellular adhesion through the phosphorylation of
p120-catenin (p120), cofilin, plakophilin 3, pyk2, talin and integrin
b4. Therefore, CSF-1R induces tyrosine phosphorylation of many
proteins that are also regulated by EGFR.
Due to the frequent activation/over-expression of ERBB2/
HER2 in mammary epithelial tumors, we also examined the
overlap between CSF-1R-induced changes in tyrosine phosphor-
ylation and changes induced by this RTK. Phosphoproteomic
analysis of tyrosine-phosphorylated proteins in ERBB2-overex-
pressing breast and ovarian cancer cell lines identified 78 proteins
with increased phosphorylation [32], 12 of which overlapped with
the CSF-1R- induced and CSF-1R induced* proteins (p120,
EPHA2, ACK, integrin b4, HGF-R, KIRREL, caveolin-1,
EGFR, GAB1, CDC2, PI3-K p85 alpha, and ERK2). In a similar
analysis, Bose and colleagues identified 198 proteins with
increased tyrosine phosphorylation in ERBB2-over-expressing
NIH-3T3 cells using a quantitative MS approach [33]; only 19
of these overlap with the CSF-1R induced and CSF-1F induced*
Protein Name UniProt# NCBI Site Fold change* (CA-CSF-1R/MCF-10A) Fold change* (CA-CSF-1R/Y561F) Src regulation
PZR O95297 Y263 12.21;10.01;7.27;7.27 0.62;0.62;0.6;0.6 Src-inhibited
NHP2L1 P55769 Y31 .16.86 0.62 Src-inhibited
Cdc2 P06493 Y15 4.69;4.69;4.18 0.79;0.61;0.55;0.55;0.55;0.49;0.49 Src-inhibited
H2B1L Q99880 Y42 .113.37 0.53;0.53;0.42;0.42 Src-inhibited
CNP P09543 Y110 2.8 0.48; 0.48; 0.44 Src-inhibited
CDK3 Q00526 Y19 870.42;4.62 0.52; 0.52 Src-inhibited
*Multiple peptides were detected for tyrosine sites with multiple values.
doi:10.1371/journal.pone.0013587.t001
Table 1. Cont.
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caveolin, cct-theta, p120, PI3K p85-beta, intersectin 2, LDH-A,
PGK1, PKM2, PI3K p85-alpha, PTRF, vimentin, HSP90-b,
glutathione-S-transferase, RAN and YES). The lack of extensive
overlap with CSF-1R-induced phosphoproteins in both ERBB2
studies could in part reflect cell-type differences (fibroblasts vs.
mammary epithelial), species differences (mouse vs. human), and
differing receptor activities (ERBB2 vs. CSF-1R). It is also possible
that under-sampling contributes to the disparities between the
studies due to the nature of MS-based studies.
We identified three proteins with increased tyrosine phosphor-
ylation in all the proteomic datasets. CSF-1R, EGFR and ERBB2
activation all increase the tyrosine phosphorylation of p120,
caveolin and PI3-K p85-alpha, suggesting that they are key
common substrates of RTK activation. In addition, phosphory-
lation of ACK, calmodulin, EPHA2, integrin b4, intersectin 2,
KIRREL, HGF-R, GAB1, CDC2, ERK2, annexin A2, and PI3-
K p85-beta were induced by CSF-1R and identified in at least one
of the other three proteomic datasets analyzed for RTK-induced
tyrosine phosphorylation indicating that their phosphorylation is
not unique to CSF-1R.
From the comparative analysis, we determined that 35 of the
CSF-1R induced phosphoproteins did not overlap with those
identified in any of the analyzed RTK studies (Table 4). Of these
35 proteins, we were able to link 16 of these proteins to the CSF-
1R pathway using Ingenuity IPA, a database of protein-protein
interactions curated from the literature, allowing one or two
intermediate signaling proteins. However, the remaining 19 of
these proteins including ACLY, CNP, UBXD8, GUK 1, H2B1L,
H2B2E, LDH-B, KIAA0323, NHP2L1, PDLIM5, PIN4, RPS27,
SLC20A1, STEAP1, TAOK1, TJAP1, urdpase1, UQCRC2, and
ZDHHC7 could not be linked to the CSF-1R pathway and thus
represent novel CSF-1R targets (Table 4). Many of these proteins
are not well characterized, and thus could lead to new insights into
the biological consequences of CSF-1R activity in epithelial cells
and its role in epithelial tumorigenesis.
Y561-dependent, putative SRC-dependent, changes in
tyrosine phosphorylation
To identify putative SRC targets, we examined whether the
detected changes in tyrosine phosphorylation are dependent on
Y561 by comparing the phosphotyrosine profile of cells expressing
the CA-CSF-1R Y561F mutant, which is unable to recruit SRC,
to that of cells expressing the CA-CSF-1R. For the CA-CSF-1R/
CA-CSF-1R Y561F comparison, fold change ratios .1.55 were
defined as an upregulation in the levels of tyrosine phosphoryla-
tion, ratios 0.63–1.55 as unchanged, and ratios ,0.63 as a
downregulation of tyrosine phosphorylation (See Materials and
Methods and Table S3). As Y561 is not exclusively selective for
SRC, we cannot distinguish SRC substrates from those of other
SFKs, and thus all peptides specifically detected in the CA-CSF-
1R Y561F expressing cells are not necessarily exclusively SRC-
regulated. It is also possible that other proteins in addition to SRC
family kinases can bind to this site; however, we will refer to the
Y561-dependent changes as SRC-dependent for simplicity of
nomenclature. Tyrosine phosphorylated peptides were found to
fall into three different categories based on the Y561 site: ‘‘SRC-
independent’’ sites displayed no differences in tyrosine phosphor-
ylation between CA-CSF-1R and CA-CSF-1R Y561F cells;
‘‘SRC-dependent’’ sites demonstrated an increase in tyrosine
phosphorylation in CA-CSF-1R cells compared to CA-CSF-1R
Y561F cells; and ‘‘SRC-inhibited’’ sites showed higher phosphor-
ylation in the CA-CSF-1R Y561F cells as compared to CA-CSF-
1R cells (Table 1, Table S3).
Earlier studies have demonstrated that the CSF-1R Y561F
mutation impairs the ligand-dependent auto-phosphorylation of
CSF-1R; however, the Y561F mutation did not compromise the
auto-phosphorylation of CA-CSF-1R in this analysis as both the
activation loop residue, Y809, and Y873 had equal levels of
tyrosine phosphorylation between CA-CSF-1R and CA-CSF-1R
Table 2. Proteins with CSF-1R induced* tyrosine
phosphorylation detected in CA-CSF-1R v CA-CSF-1R Y561F
analysis.
Protein
Name UniProt# NCBI Site
Fold
change Src regulation
STAT 5A P42229 Y694 2.11;2.11 Src-dependent
EphB4 P54760 T587, Y595 2.09 Src-dependent
RAN P62826 Y146 1.81 Src-dependent
SPG20 Q8N0X7 Y46 1.66 Src-dependent
RPS13 P62277 Y37 1.49 Src-independent
PIK3R3 Q92569 Y373 1.43 Src-independent
HGF-R P08581 Y1234 1.21;1.21 Src-independent
Cofilin P23528 Y139 1.14;0.79 Src-independent
p38-alpha Q16539-2 Y182 1.03;1.03 Src-independent
Insulin
Receptor
P06213 Y1185, Y1189 0.77;0.77 Src-independent
EphA2 P29317 Y594 0.74;0.74 Src-independent
Transferrin
receptor
P02786 S19 1.28 Src-independent
LDH-B P07195 Y239 1.23 Src-independent
KIRREL Q96J84 Y724 1.17 Src-independent
FLJ20625 Q9NWT0 Y140 1.13 Src-independent
GUK1 Q16774 Y52 1.03 Src-independent
Yes P07947 Y221 0.99 Src-independent
D-Prohibitin Q99623 Y121 0.95 Src-independent
MGC14839 Q96A22 Y78 0.92 Src-independent
ADK2 P54819 Y200 0.86 Src-independent
ADK2 P54819 Y199 0.86 Src-independent
KIRREL Q96J84 Y605 0.85 Src-independent
Crk P46108 Y221 0.77 Src-independent
Caveolin 1 Q03135 Y25 0.69 Src-independent
Pyk2 Q14289 Y579, Y580 0.67 Src-independent
STEAP1 Q9UHE8 Y27 0.66 Src-independent
KRT81 Q14533 Y282 0.64 Src-independent
CDK3 Q00526 T14, Y15 0.61;0.61 Src-inhibited
NDUFB10 O96000 Y54 0.62 Src-inhibited
SHC1 P29353 Y350 0.62 Src-inhibited
PGK1 P00558 Y196 0.61 Src-inhibited
EGF-R P00533 Y1197 0.6 Src-inhibited
ZDHHC5 Q9C0B5 S529 Y533 0.53 Src-inhibited
PI3K p110
alpha
P42336 Y508 0.45 Src-inhibited
GAB1 Q13480 Y406 0.27 Src-inhibited
MGC32065 Q8WV41 Y264 0.22 Src-inhibited
H2B1L Q99880 Y40 0.43 Src-inhibited
PTRF Q6NZI2 Y156 0.45;0.45 Src-inhibited
doi:10.1371/journal.pone.0013587.t002
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at the Grb2 binding site, Y699, and Y923, supporting the
conclusion that the total kinase activity of CSF-1R was not
significantly affected by the Y561F mutation (Table S3). In
addition, our previous data indicates that the CA-CSF-1R Y561F
is equally competent for signaling as it can induce growth factor
independence in MCF-10A cells and promote MCF-10A acini
growth similar to CA-CSF-1R [8]. The previously reported defects
in autophosphorylation may not be relevant in the context of the
active variant of the receptor in which point mutations permit
ligand-independent receptor activation and inhibit the receptor
downregulation via internalization.
Quantitative comparison of the differences in peptide tyrosine
phosphorylation between CA-CSF-1R and CA-CSF-1R Y561F-
expressing cells identified 22 tyrosine sites on 19 proteins
dependent on CA-CSF-1R Y561 that were phosphorylated above
threshold (ratio .1.55, see Materials and Methods) (Table 5).
Although phosphorylation of SRC at its activation site (Y418) was
not detected in cells expressing either form of CSF-1R, CA-CSF-
1R was highly phosphorylated at Y561 indicating that this site is
competent to recruit and activate SRC. In addition, known SRC
targets including p120, ACK, and Hrs demonstrated a Y561-
dependent increase in phosphorylation. b-adaptin, intersectin 2,
and KIAA1217 were also identified as having SRC-dependent
tyrosine phosphorylation sites. Furthermore, this analysis provided
supporting evidence of Src regulation of the following sites:
Integrin b4 Y1510, FLJ20625 Y40, Hrs Y334, TJAP1 Y352 and
ZDHHC7 Y130. These sites were identified as SRC-dependent in
CA-CSF-1R expressing MCF-10A cells in a previous non-
quantitative LC-MS/MS study (data not shown, Figure 3C).
53% (171/324) of the peptides detected in the CA-CSF-1R vs.
CA-CSF-1R Y561F comparison were classified as SRC-indepen-
Table 3. Profile of known CSF-1R induced changes in tyrosine phosphorylation in MCF-10A cells.
Protein Name UniProt # NCBI Site Fold change (CA-CSF-1R/MCF10A) Function
Annexin A1 P04083 Y38 19.83 Calcium-binding protein
CSF-1R P07333 Y923 .133.30 Receptor tyrosine kinase (RTK)
CSF-1R P07333 Y873 .56.43 RTK
CSF-1R P07333 Y809 .45.71 RTK
CSF-1R P07333 Y699 .38.88 RTK
CSF-1R P07333 Y873 .38.15 RTK
CSF-1R P07333 Y561 .37.45 RTK
CSF-1R P07333 Y699 .32.34 RTK
CSF-1R P07333 Y809 .20.07 RTK
CSF-1R P07333 Y699 .13.82 RTK
CSF-1R P07333 Y699 .8.52 RTK
CSF-1R P07333 Y556 .5.68 RTK
CSF-1R P07333 Y809 1292.56 RTK
ERK 1 P27361 Y204 27.99 Protein kinase, Ser/Thr
ERK 2 P28482 T184, Y186 56.77 Protein kinase, Ser/Thr
PIK3R1 P27986 Y580 .56.64 Kinase, lipid
PIK3R1 P27986 Y470 .24.59 Kinase, lipid
PIK3R1 P27986 Y607 .22.45 Kinase, lipid
PIK3R1 P27986 Y580 79.89 Kinase, lipid
PIK3R1 P27986 Y580 36.8 Kinase, lipid
PIK3R1 P27986 Y580 36.73 Kinase, lipid
PIK3R1 P27986 Y467 6.15 Kinase, lipid
PIK3R2 O00459 Y577 .13.95 Kinase, lipid
PKC delta Q05655 Y374 .9.84 Protein kinase, Ser/Thr
SHC1 P29353 Y427 5.87 Adaptor/scaffold
SHC1 P29353 Y427 5.87 Adaptor/scaffold
SHC1 P29353 Y427 5.53 Adaptor/scaffold
SHC1 P29353 Y427 5.53 Adaptor/scaffold
STAT3 P40763 Y705 4.76 Transcription factor
STAT3 P40763 Y705 4.76 Transcription factor
STAT3 P40763 Y705 4.64 Transcription factor
STAT3 P40763 Y705 4.64 Transcription factor
Vimentin P08670 Y61 2.01 Cytoskeletal protein
Vimentin P08670 Y53 2.15 Cytoskeletal protein
doi:10.1371/journal.pone.0013587.t003
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PLoS ONE | www.plosone.org 8 October 2010 | Volume 5 | Issue 10 | e13587Figure 2. CSF-1R-induced changes in tyrosine phosphorylation. A) GeneGOH enrichment analysis of proteins with CSF-1R-induced and CSF-
1R-induced* tyrosine phosphorylation. The 20 most significant GeneGOH Processes (black) and 5 most significant diseases (blue) are shown.
Enrichment scores are 2log(p-value). B) Diagram depicting the overlap in phosphorylated proteins between the CSF-1R, EGFR and ERBB2 pathways.
Thirty-five proteins were unique to CSF-1R (blue), nineteen were in one other pathway (light gray), fourteen were in two (dark gray), and three were
common to all studies (green). The EGFR/CSF-1R overlapping proteins are listed in Table S5.
doi:10.1371/journal.pone.0013587.g002
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adhesions were phosphorylated in a SRC-independent manner,
including paxillin Y88, Y118, FAK Y576, p130Cas Y128, Y234,
Y267, Y249, Y327, Y387, talin Y70 and integrin b4 Y1207. Since
many of these are known targets of SRC, it is likely that SRC
molecules activated by integrin receptor engagement, rather than
SRC recruitment to CSF-1R, are responsible for these phosphor-
ylation events.
35% (112/324) of peptides detected were classified as SRC-
inhibited (Table S2). These peptides contained sites that displayed
elevated levels of phosphorylation in CA-CSF-1R Y561F-express-
ing cells, raising the possibility that SRC/SFKs may negatively
regulate these sites. Proteins with phosphorylated tyrosine sites that
were higher in the Y561F mutant-expressing cells included
caveolin, vimentin, DLG1, and DLG3, among others (Table
S3). One possible explanation for this finding is that SRC activates
a phosphatase that targets these proteins. Alternatively, it is
possible that CSF-1R-induced changes in cellular adhesion could
alter the localization of SRC modifying its access to specific
substrates and thus leading to distinct patterns of tyrosine
phosphorylation dependent on the Y561 site.
Motif analysis of SRC-regulated peptides
To determine whether the peptides that exhibited putative
SRC-dependent phosphorylation sites were enriched for specific
sequences flanking the tyrosine phosphoacceptor, we utilized an
on-line extraction algorithm, Motif-X (motif-x.med.harvard.edu),
developed by Schwartz and Gygi [36,37]. This algorithm identifies
the most frequently occurring residues in positions surrounding the
pY and provides statistical information on the significance of their
Table 4. Proteins with increased tyrosine phosphorylation unique to CSF-1R.
Protein Name UniProt # NCBI Site Classification
TAOK1 Q7L7X3 Y309 CSF-1R induced
UBXD8 Q96CS3 Y79 CSF-1R induced
UQCRC2 P22695 Y207 CSF-1R induced
SPG20 Q8N0X7 Y46 CSF-1R induced*, Src-dependent
ADK2 P54819 Y199 CSF-1R induced*, Src-independent
D-PROHIBITIN Q99623 Y121 CSF-1R induced*, Src-independent
GUK1 Q16774 Y52 CSF-1R induced*, Src-independent
KRT81 Q14533 Y282 CSF-1R induced*, Src-independent
LDH-B P07195 Y239 CSF-1R induced*, Src-independent
PI3K p85-gamma Q92569 Y373 CSF-1R induced*, Src-independent
STEAP1 Q9UHE8 Y27 CSF-1R induced*, Src-independent
CDK3 Q00526 T14, Y15 CSF-1R induced*, Src-inhibited
NDUFB10 O96000 Y54 CSF-1R induced*, Src-inhibited
PI3-kinase p110 alpha P42336 Y508 CSF-1R induced*, Src-inhibited
CSF-1R P07333 Y561 CSF-1R induced, Src-dependent
FLJ20625 Q9NWT0 Y40 CSF-1R induced, Src-dependent
KIAA0323 O15037 Y456 CSF-1R induced, Src-dependent
TJAP1 Q5JTD0 Y352 CSF-1R induced, Src-dependent
ZDHHC7 Q9NXF8 Y130 CSF-1R induced, Src-dependent
INSULIN RECEPTOR P06213 Y1189 CSF-1R induced, Src-independent
PIN4 Q9Y237 Y122 CSF-1R induced, Src-independent
PKC Delta Q05655 Y374 CSF-1R induced, Src-independent
RPS27 P42677 Y31 CSF-1R induced, Src-independent
ACLY P53396 Y1073 CSF-1R induced, Src-inhibited
CNP P09543 Y110 CSF-1R induced, Src-inhibited
DLG1 Q12959 Y760 CSF-1R induced, Src-inhibited
Enolase 1 P06733 Y188 CSF-1R induced, Src-inhibited
H2B1L Q99880 Y42 CSF-1R induced, Src-inhibited
H2B2E Q16778 Y43 CSF-1R induced, Src-inhibited
HGK O95819 Y1227 CSF-1R induced, Src-inhibited
NHP2L1 P55769 Y31 CSF-1R induced, Src-inhibited
PDLIM5 Q96HC4 Y251 CSF-1R induced, Src-inhibited
SLC20A1 Q8WUM9 Y388 CSF-1R induced, Src-inhibited
UrdPase 1 Q16831 Y35 CSF-1R induced, Src-inhibited
VASP P50552 Y38 CSF-1R induced, Src-inhibited
doi:10.1371/journal.pone.0013587.t004
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in the detected phosphopeptides, peptide sequences were centered
around the phosphorylated tyrosine residue, and the significance
threshold was set to p,0.0001 with a minimum number of
occurrences for a particular sequence set to four because of the
relatively small number of peptides analyzed. Because of the
limited number of SRC-dependent peptides, we included all
peptides with fold change values within one standard deviation of
the mean (.1.32). While statistically the detected changes in
phosphorylation of peptides with fold change values 1.32–1.55 are
less likely to be significant, this set of peptides includes known SRC
targets such as p120 and p130Cas, supporting the hypothesis that
such peptides may in fact be regulated by CSF-1R-induced SRC
activation.
The extracted motif as shown in Figure 3A very closely resembles
the previously identified consensus c-SRC kinase substrate motif, D
[ED] [EDG] [IVL] Y# [GE] E [FI] F [37]. Recent work by
Schwartz and colleagues has led to the development of more
informative sequence motif representation using Motif-X pLOGos
(probability log-based logos) (Schwartz, Chou and Church,
unpublished data). Residues closest to the midline in the pLOGos
motif representation have the greatest degree of correlation. Those
residues above the midline are overrepresented while those below
the midline are underrepresented. The red line indicates a p,0.01.
The height of the residue symbol is proportional to the correlation
values of the residue at that position, and fixed positions within the
sequence are indicated with only one residue.
The motif analysis identified a high selectivity for proline at the
+3 position in the SRC-dependent phosphopeptides. Peptides
derived from p120, p130Cas, STAT5A, EPHA2, KIAA1217 and
ZDHHC7 have a proline at the +3 position. pLOGos represen-
tations of SRC consensus motifs derived from annotated substrates
Table 5. SRC-dependent tyrosine phosphorylated peptides identified in the comparison of CA-CSF-1R to CA-CSF-1R Y561F MCF-
10A cells.
Protein Name NCBI Site Peptide Sequence Fold change Function
CSF-1R Y561 K.IIESYEGNSY#TFIDPTQLPYNEK‘WEFPR@.N .16.44 Receptor tyrosine kinase
p120catenin Y904 K.SLDNNY#STPNER.G 5.31 Adhesion
Hrs Y132 K.VVQDTY#QIMK‘VEGHVFPEFK‘.E 5.06 Adaptor/scaffold
Hrs Y334 R.YLNR@NY#WEK‘.K 4.49 Adaptor/scaffold
TJAP1 Y352 R.NSPLPNCTY#ATR@.Q 4.31 Adhesion
ZDHHC7 Y130 K.EYMESLQLK‘PGEVIY#K‘.C 4.05 Unknown function
ZDHHC7 Y130 K.EYMESLQLK‘PGEVIY#K‘.C 3.99 Unknown function
ZDHHC7 Y130 K.EYMESLQLKPGEVIY#KCPK.C 3.98 Unknown function
Hrs Y216 R.VCEPCY#EQLNR.K 3.51 Adaptor/scaffold
Hrs Y216 R.VCEPCY#EQLNR@.K 3.5 Adaptor/scaffold
Ack Y518 K.KPTY#DPVSEDQDPLSSDFKR.L 3.45 Protein tyrosine kinase
Hrs Y132 K.YKVVQDT#YQIMK.V 3.12 Adaptor/scaffold
Hrs Y132 K.VVQDTY#QIMK‘.V 3.11 Adaptor/scaffold
Intersectin 2 Y552 K.LIY#LVPEK.Q 2.73 Adaptor/scaffold
Hrs Y132 K.YK‘VVQDTY#QIMK‘.V 2.63 Adaptor/scaffold
ATP1A1 Y260 R.GIVVY#TGDR.T 2.62 Hydrolase
KIAA0323 Y456 R.HIVIDGSNVAMVHGLQHY#FSSR.G 2.22 Unknown function
Beta-adaptin Y276 K.DSDY#YNMLLK‘.K 2.12 Vesicle protein
Stat 5A Y694 K.AVDGY#VKPQIK.Q 2.11 Transcription factor
EphA2 Y575 R.QSPEDVY#FSK‘.S 2.11 Receptor tyrosine kinase
EphB4 T587, Y595 K.HGQYLIGHGT#KVYIDPFTY#EDPNEAVR.E 2.09 Receptor tyrosine kinase
FLJ20625 Y40 K.ALNGAEPNY#HSLPSAR@.T 2.06 Unknown function
KIAA0323 Y456 R.HIVIDGSNVAMVHGLQHY#FSSR@.G 1.98 Unknown function
RAN Y146 K.NLQY#YDISAK.S 1.81 Nuclear receptor co-regulator,
G protein
PLEKHA6 Y492 R.SEDIY#ADPAAYVMR@.R 1.79 Lipid binding protein
EphB4 Y774 R.FLEENSSDPTY#TSSLGGKIPIR.W 1.75 Receptor tyrosine kinase
KIAA0323 Y456 R.HIVIDGSNVAM*VHGLQHY#FSSR@.G 1.7 Unknown function
SPG20 Y46 K.GLNTDELGQKEEAKNYY#K.Q 1.66 Unknown function
KIAA1217 Y393 R.NEGFY#ADPYLYHEGR.M 1.6 Unknown function
Integrin b4 Y1510 R.SEHSHSTTLPR@DY#STLTSVSSHDSR@.L 1.59 Adhesion, Receptor
# indicates phosphorylation.
* indicates oxidation.
@ indicates ‘‘heavy’’ arginine.
‘ indicates ‘‘heavy’’ lysine.
doi:10.1371/journal.pone.0013587.t005
RTK-Induced SRC substrates
PLoS ONE | www.plosone.org 11 October 2010 | Volume 5 | Issue 10 | e13587Figure 3. Y561-dependent changes in phosphorylation are SRC-dependent changes in tyrosine phosphorylation. A) pLOGos
representation of motif extracted from the SRC dependent substrates identified in the quantitative MS analysis. Also shown are motif representations
generated from collections of known SRC targets in PhosphoSiteH Plus, Phospho.ELM and ScanSite, respectively. B) GeneGOH enrichment analysis of
the SRC-dependent proteins using the .1.32 inclusive threshold. C) Validation of SRC-dependent differential tyrosine phosphorylation detected in a
pilot qualitative MS analysis by quantitative MS analysis. Because the pilot experiments did involve the isotopic labeling of cellular proteins, the
qualitative MS analysis was designed only to detect the presence of tyrosine phosphorylated peptides isolated by phosphotyrosine
immunoprecipitation. D) Western blot analysis of SRC, Stat5 and Hrs tyrosine phosphorylation. Lysates from CA-CSF-1R cells treated with either
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are shown in Figure 3A [38,39]. The same preference for a
hydrophobic residue at the +3 position appears in each of these
motifs. Interestingly, Schwartz and Gygi uncovered this same
preference in an analysis of two phosphotyrosine proteomic data
sets generated by pervanadate-induced phosphorylation in Jurkat
cells and c-SRC Y527F-stimulated phosphorylation in NIH-3T3
cells [23,36]. The SRC consensus representations also clearly
indicate a preference for acidic residues at positions 24, 23, 22,
and +1; the motif extracted from the CSF-1R-induced SRC
substrates has the same profile. Thus, while the nature of this study
does not allow us to distinguish between direct and indirect SRC
substrates, this motif analysis of the Y561-dependent phosphory-
lation sites suggest that many are in fact direct SRC substrates
since the most prominent sequence motif closely matches known c-
SRC consensus motifs [36,37]. In addition, the motif analysis
validated the inclusion of phosphopeptides with fold change values
1.32–1.55 and provided evidence that these sites may be SRC
regulated since many closely match the SRC consensus motif.
Enrichment Analysis of the SRC-dependent peptides
To derive information on the cellular functions of the SRC-
dependent substrates, we performed an enrichment analysis. This
analysis included all SRC-dependent phosphorylated proteins with
a fold change .1.32 (Table S2). Three of the cellular processes
found to be overrepresented in this set of substrates were related to
some aspect of cell adhesion including the regulation of cell
junctions and cadherins (Figure 3B). The enrichment identified
p120, plakophilin 4, erbin, EPHA2, EPHB4, and PIK3R3 as
proteins associated with the regulation of cell junctions and
cadherins; these proteins may be candidate mediators of the CSF-
1R-induced SRC-dependent adhesion disruption.
Validation of differential tyrosine phosphorylation
While it wasn’t feasible to validate a large number of tyrosine
phosphorylation sites identified in this screen, six of the proteins
identified in the SILAC analysis overlap with SRC-dependent
substrates identified in a pilot, non-quantitative MS analysis
(Figure 3C and data not shown). We also validated the SRC-
induced tyrosine phosphorylation of two substrates, Hrs and
STAT5A (Figure 3D). CA-CSF-1R-expressing MCF-10As were
treated with the SRC kinase inhibitor, SU6656, overnight prior to
analysis. Treatment with the inhibitor decreased phosphorylation
of the SRC active site (Y418) (Figure 3D), validating the efficacy of
the inhibitor. Tyrosine phosphorylation of STAT5A Y694 was
reduced in the SU6656-treated CA-CSF-1R cells, and the CSF-
1R Y561F did not induce phosphorylation of the site. In addition,
we observed that tyrosine phosphorylation of Hrs was not induced
by the CSF-1R Y561F. While we were unable to define which sites
on Hrs were phosphorylated, this evidence validates that
phosphorylation of this protein is SRC-dependent.
Analysis of tyrosine phosphorylation in human cancer
phosphoproteomic datasets
To address the relevance of the identified SRC substrates to
tumorigenesis, we conducted comparative bioinformatics analysis
on phosphoproteomic datasets generated from human tumor
samples. Because we profiled CSF-1R-induced and SRC-depen-
dent changes in tyrosine phosphorylation in a mammary epithelial
cell line, we first analyzed a small breast cancer dataset, derived
from only eight tumors, available publicly from CST’s Phospho-
SitePlusH [38]. Many SRC-dependent sites identified in our study
were tyrosine phosphorylated in these human breast tumors
(Table 6). The small size of the dataset and the detection of
activated SRC in all eight tumors precluded a rigorous correlation
vehicle control or the SRC kinase inhibitor, SU6656, were analyzed for changes in tyrosine phosphorylation using phospho-specific antibodies for SRC
Y418 and Stat5 Y694. Hrs immunoprecipitates from Parental, CA-CSF-1R and CA-CSF-1R Y561F MCF-10As were probed with a phosphotyrosine
antibody.
doi:10.1371/journal.pone.0013587.g003
Table 6. Comparative analysis of tyrosine phosphorylation detected in human breast tumors.
Protein Name NCBI site Fold change (CA-CSF1R/Y561F) # of tumors Tumors* with phosphorylation
Src Y418 - 8 1, 2, 3, 4, 5, 6, 7, 8
H I P K 3 3 5 9 1 . 4 3 8 1 ,2 ,3 ,4 ,5 ,6 ,7 ,8
STAT5A 694 2.11 7 2, 3, 4, 5, 6, 7, 8
p120catenin 904 5.31 6 1, 2, 4, 5, 6, 8
H r s 2 1 6 3 . 5 1 5 1 ,3 ,4 ,5 ,8
Frk 46 1.41 5 1, 3, 6, 7, 8
Ack 518 3.45 4 1, 4, 5, 6
Hrs 132 5.06 2 2, 4
ATP1A1 260 2.62 1 2
p120catenin 228 1.53 1 2
*Tumor# PhosphoSite PlusH ID.
1 BC0001.
2 BC0002.
3 BC0003.
4 BC0004.
5 BC0005.
6 BC0007.
7 BC0008.
8 csBC0001.
doi:10.1371/journal.pone.0013587.t006
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However, several putative SRC substrates, including HIPK3,
STAT5A, p120, FRK and Hrs, were frequently phosphorylated in
multiple breast tumors.
Given the limited amount of phosphotyrosine proteome data
available from breast tumor dataset, we also analyzed a larger set
of phosphoproteomic data derived from human non-small cell
lung cancer. Rikova and colleagues analyzed the phosphorylation
of proteins in 150 human NSCLC lung tumors using PhosphoS-
canH analysis [40]. Activating mutations of EGFR are frequently
found in NSCLC tumors, and EGFR activation can similarly
induce the upregulation of endogenous c-SRC. We performed
correlation studies to determine the substrates whose phosphor-
ylation significantly correlated with SRC activity based on
detection of the phosphorylation of Y418 SRC autophosphoryla-
tion site.
The comparison revealed that many SRC-dependent proteins
were also tyrosine phosphorylated in human lung tumors. Five
proteins (p120, p130Cas, FRK, Hrs and KIAA0323) showed a
significant correlation (p-value,0.05) between SRC activation and
tyrosine phosphorylation (Table 7). Three of these five proteins
(p120, Hrs, and FRK) were also commonly tyrosine phosphory-
lated in the human breast cancer dataset. This finding of
significant co-regulation of SRC activity and substrate phosphor-
ylation indicate that these may be critical SRC substrates in the
context of a human epithelial tumor. Together, our analyses
suggest that a subset of the SRC-dependent substrates we
identified downstream of CSF-1R induced SRC activation are
relevant in human epithelial tumorigenesis. Substrates such as
p120, Hrs, Ack, p130Cas and FRK may be key mediators of SRC
signaling in human tumors and contribute directly to SRC-
mediated events during tumor progression.
Discussion
The quantitative MS analysis performed in this study identified
proteins phosphorylated downstream of CSF-1R activation in
mammary epithelial cells and defined a specific set of these
proteins as candidate targets of SRC family kinases. While earlier
studies have identified CSF-1R and SRC targets phosphorylated
in other cell types, some of which were detected in this analysis,
previously unrecognized targets of these kinases were also revealed
in this study. Comparative analysis with other RTK tyrosine
phosphoproteomic datasets revealed multiple overlapping pTyr
substrates in CSF-1R-, EGFR- and ERBB2-expressing cells and
highlighted the shared regulation of caveolin, p120 and PI3-K by
these RTK pathways. Many of the putative SRC substrates
including p120, Hrs and STAT5A are likely direct SRC targets
based on the degree of overlap between the peptides detected and
the known SRC consensus motif, as well as the observed
downregulation of tyrosine phosphorylation by pharmacological
inhibition of SRC kinase activity. In addition, the phosphorylation
of several SRC substrates significantly correlated with SRC
activation in human lung tumors. Substrates that correlated with
SRC activation, such as p120, Hrs, p130Cas, FRK and
KIAA0323, may be critical mediators of SRC activity in human
tumors.
CSF-1R signaling
The CSF-1 pathway is required for macrophage differentiation
and survival, yet previous work suggests the CSF-1 pathway may
also drive tumor cell progression. Our data delineate the changes
in tyrosine phosphorylation induced by CSF-1R signaling in
epithelial cells. Unlike substrates of EGFR and ERBB2, CSF-1R
targets in epithelial cell have not been well characterized. Like
other growth factor receptor tyrosine kinases, CSF-1R induces
pleiotropic phenotypic alterations in epithelial cells. CSF-1R
activation in MCF-10A cells induces cell-cell adhesion disruption,
loss of contact inhibition, growth in soft agar, and enhanced cell
motility [8,41]. In addition, recent studies showed that invasion by
a human breast tumor cell line is dependent on paracrine signaling
with host macrophages as well as autocrine signaling involving
CSF-1R expressed on tumor cells themselves [14]. The candidate
substrates identified in our analysis (e.g. p120, integrin b4,
plakophilin 3, STAT3 and vimentin) will inform future studies
addressing the mechanisms involved in CSF-1R-induced tumor
progression.
Using comparative bioinformatic analysis, we found that CSF-
1R modified a set of proteins which did not overlap with those
phosphorylated downstream of other RTKs e.g., EGFR and
ERBB2. From this set of 35 proteins, we identified 19 proteins,
which had not been previously linked to CSF-1 signaling based on
studies published to date; these proteins may represent substrates
unique to CSF-1R signaling. These proteins regulate a number of
different cellular processes including trafficking, cell cycle
progression and cell polarity and exhibit such diverse functions
as kinases, adaptors and structural proteins. Many of these
proteins are not well characterized; thus studies of these putative
novel targets may reveal new mechanistic insights into epithelial
cell biology and tumorigenesis. For example, two of these proteins,
ACLY and UQCRC2, play a role in the regulation of cellular
metabolism. ACLY, ATP citrate lyase, is an enzyme involved in
the conversion of glucose to cytosolic acetyl CoA, which is a part of
the glucose-dependent lipogenesis pathway [42,43]. UQCRC2,
ubiquinol-cytochrome C reductase complex III protein 2, is a
protein involved in oxidative phosphorylation and is a subunit of
the mitochondrial cytochrome bc1 complex. Cancer cells undergo
changes in metabolism in order to shift to the metabolic demands
of proliferative cells [44,45]. Interestingly, ACLY can be
phosphorylated and activated by Akt [46]. Upregulation of ACLY
activity in tumor cells expressing activated Akt could suppress fatty
acid oxidation (through increased acetyl-CoA and malonyl-CoA
production), thus supporting the significant requirement for lipid
synthesis in proliferative cell states. Serine phosphorylation of
ACLY in non-small cell lung cancer cell lines has been shown to
upregulate ACLY activity and siRNA-mediated KD of the protein
induces growth arrest [43]. ACLY expression is increased in
metastatic breast cancer lines in comparison to non-tumorigenic
and non-metastatic cell lines [42]. These data could suggest a role
for ACLY in breast metastasis and its phosphorylation in the
regulation of protein function. In our study, CSF-1R activation
induced a 26-fold increase in tyrosine phosphorylation of ACLY at
Table 7. Comparative analysis of tyrosine phosphorylation
detected in human lung tumors.
Protein Name NCBI Site
Fold change
(CA-CSF-1R/Y561F) p-Value
p130Cas Y234 1.37 0.001993
p120catenin Y228 1.53 0.004847
p120catenin Y904 5.31 0.013537
Frk Y46 1.41 0.017747
Hrs Y216 3.5 0.021389
KIAA0323 Y502 2.22 0.037628
doi:10.1371/journal.pone.0013587.t007
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ACLY by tyrosine phosphorylation. Similarly, UQCRC2 levels
are altered in cancer cells, showing a decrease in mitochondria
from breast cancer cells as compared to normal breast cells [47].
Since we detected a 10-fold increase in CSF-1R-dependent
phosphorylation of UQCRC2, this raises that possibility that this
modification may downregulate it’s activity, thus causing a similar
loss of activity as observed in tumor cells with lower levels of
UQCRC2 expression. The changes in tyrosine phosphorylation
on proteins involved in metabolism highlight candidate effectors
that may contribute to altered metabolism in CSF1-1R-driven
phenotypes.
CSF-1R-induced, SRC substrates
As the first characterized proto-oncogene, SRC has been
extensively studied in human tumors; however, SRC itself is not
frequently mutated, and on its own is not strongly transforming.
The increased activation of SRC detected in tumor cells may
therefore result from upstream activated RTKs [10]. CSF-1R-
induced SRC activation may mimic the upregulation of SRC
activity by RTKs in human tumors. Therefore, CSF-1R-induced
SRC-dependent substrates are likely more relevant to tumorigenesis
than substrates of overexpressed c-SRC or activated mutants of the
protein. Surprisingly, comparison of SRC substrates identified in
our study to SRC targets identified in other MS-based studies
revealed relatively small overlap (data not shown) [22,23,24,25,26].
This may be due to the use of overexpressed or constitutively active
SRC in these studies, which may lead to phosphorylation of a
broader set of substrates distinct from those targeted by RTK-
induced SRC activity. SRC can be activated by multiple classes of
membrane receptors, such as G protein-coupled receptors, cell
adhesion molecules, and integrins. Overexpression of wild-type or
activated SRC mutants may induce phosphorylation of this broader
subset of targets distinct from the substrates of endogenous c-SRC
activated by an upstream growth factor receptor.
SRC activity and substrate phosphorylation is tightly controlled
in vivo by intramolecular interactions and protein localization, and
such regulatory mechanisms are disrupted in SRC mutant variants
[5]. In our study, endogenous wild-type SRC was activated by an
upstream RTK, more closely reflecting the effects of activation of
endogenous SRC in tumor cells. Thus, our experimental design
facilitated the selective identification of targets most likely regulated
by RTK-activated SRC. Furthermore, we identified five proteins
whose phosphorylation was significantly associated with SRC
activation in human lung tumors. Of these five proteins, p120,
Hrs and FRK may be particularly relevant to SRC-driven tumor
progression. The SRC-related tyrosine kinase, FRK, was recently
demonstrated to act as tumor suppressor by attenuating AKT/
PI3Kinase signaling through its action on the phosphatidylinositol-
3,4,5-trisphosphate 3-phosphatase, PTEN [48]. FRK-mediated
phosphorylation of PTEN blocks its interaction with an E3
ubiquitin ligase and stabilizes PTEN protein. The siRNA-mediated
knockdown of FRK in MCF-10A cells resulted in depletion of
PTEN, and its loss was sufficient to cause transformation [49]. As
such, our finding of a significant correlation between SRC activity
and FRK tyrosine phosphorylation in human lung tumors raises the
possibility that SRC-mediated phosphorylation of FRK may
negatively regulate FRK functions.
CSF-1R-SRC-induced adhesion disruption – regulators of
E-cadherin surface stability
Our study aimed to define the CSF-1R induced, SRC-regulated
proteins in part to identify candidate SRC substrates that may
regulate cell adhesion in MCF-10A cells [8]. RTK-induced SRC
activation may also be responsible for the regulation of specific
human tumor phenotypes such as cell invasion and motility, which
can increase the metastatic potential of a tumor, as SRC targets
substrates involved in the processes of cellular adhesion and
migration [50]. Elevated SRC activity is associated with
invasiveness in colon tumors, suggesting that SRC induces cellular
changes that promote tumor progression [11]. A key component of
invasive potential is the downregulation of cell-cell adhesion and
the adhesive strength of adherens junctions (AJs), which can be
accomplished by reducing surface expression of E-cadherin [51].
The oncogenic mutant v-SRC can induce the downregulation of
E-cadherin from the plasma membrane through tyrosine phos-
phorylation and ubiquitination, leading to E-cadherin degradation
in lysosomes [52,53]. However, our previous work revealed that E-
cadherin levels do not decrease in the presence of SRC activation
by CSF-1R in MCF-10As, but rather E-cadherin is redistributed
to intracellular vesicles. Thus, we hypothesized that E-cadherin is
sequestered in the cytoplasm following CSF-1R induction of SRC
activity [8].
p120 likewise regulates the stability of E-cadherin and is a well-
characterized SRC target [54]. In our study, CSF-1R induced the
tyrosine phosphorylation of p120 Y904 and Y228 in a SRC-
dependent manner (Table 5). Given the evidence that p120 is a
key regulator of cadherin stability and localization, these
phosphorylation events may be critical to the regulation of p120
function and activity. p120 has multiple tyrosine residues that can
be modified by SRC; yet the functional consequences of
phosphorylation on p120 function are not well understood
[55,56]. We observed a difference in the relative increase of
SRC-dependent phosphorylation between Y904 (5.31 fold in-
crease) and Y228 (1.53 fold). Little is known about the significance
of phosphorylated Y904, however, it has been detected in
multiple whole-cell MS-based analyses (PhosphoSite, http://
www.phosphosite.org/home). siRNA-mediated depletion of p120
dramatically disrupts cell-cell adhesion and reduces the levels of
E-cadherin and associated proteins at AJs [57]. Similarly, CSF-
1R activation of SRC leads to impaired cell-cell adhesion and re-
localization of E-cadherin. As SRC phosphorylation of p120
correlates with disruption of MCF-10A adhesion, this modifica-
tion may impair its function. SRC may further regulate p120 by
modulation of the stoichiometry of p120 phosphorylation at
specific sites.
Plakophilin 4, a p120 family member that exhibits cell type-
dependent localization to AJs and desmosomes [58], is also
tyrosine phosphorylated downstream of CSF-1R activation in a
SRC-dependent manner (Table S2). Overexpression of plakophi-
lin 4 increases surface expression of classical cadherins, and
plakophilin 4 functions similarly to p120 to stabilize cell-cell
junctions by regulating E-cadherin [54]. Intriguingly, plakophilin
4 interacts with erbin [58], which also demonstrated increased
phosphorylation at Y1104 in our study. Their coordinate
phosphorylation may be involved in SRC regulation of cell-cell
adhesion.
SRC may also influence the dynamics of cellular endocytosis
indirectly leading to the downregulation of E-cadherin. Hrs, b-
adaptin, and intersectin 2 demonstrated a SRC-dependent
increase in tyrosine phosphorylation. These proteins have been
previously shown to regulate distinct steps in endocytic trafficking
[59,60,61]. Hepatocyte growth factor-regulated tyrosine kinase
substrate (Hrs) is an important regulator of protein sorting at the
endosome. Residing at the cytoplasmic face of early endosomes
and multivesicular bodies, Hrs interacts with multiple proteins
such as clathrin and EPS15 in addition to mono- and poly-
ubiquitinated proteins via its ubiquitin-interacting motif (UIM)
RTK-Induced SRC substrates
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cadherin sorting to the lysosome requires an intact Hrs UIM, and
E-cadherin was found to associate with Hrs in an ubiquitin-
dependent manner [52]. As with p120, our data suggest that SRC
regulation of Hrs may be complex, as multiple tyrosine residues
within Hrs were modified and to varying levels.
SRC activation and substrates in human tumors
Analysis of the overlap between substrates phosphorylated in
our study and in human tumors defined a group of proteins that
may be most relevant to Src activity in human cancers: HIPK3,
STAT5A, p120, Hrs and FRK in human breast tumors, and
p130Cas, p120, FRK, Hrs and KIAA0323 in human lung tumors.
Each of these proteins has been previously implicated in cancer
onset or progression, and our data suggest that their tyrosine
phosphorylation may play a role in oncogenic changes. SRC
activity in human tumors may further coordinate the phosphor-
ylation of multiple substrates to mediate downstream phenotypes.
For example, the coordinate phosphorylation of p120 and Hrs
could be required to significantly impact E-cadherin surface
stability and disrupt cell-cell adhesion. The identification of a
critical set of SRC substrates may lead to the definition of a SRC
signature that could serve as a molecular flag that SRC is active in
a given tumor. Thus, while monitoring the phosphorylation of one
or two SRC targets may not predict response to a clinical SRC
inhibitor like dasatinib, phosphorylation of a collection of proteins
may be a more useful predictor of efficacy.
Materials and Methods
Chemicals and Antibodies
Stable isotope containing amino acids
13C6-
15N2-L-lysine and
13C6-
15N4-L-arginine were purchased from Cambridge Isotope
Labs (Andover, MA). Antibodies to SRC phospho-Y418,
STAT5A phospho-Y694, and STAT5A, were purchased from
Cell Signaling Technologies (Danvers, MA). The tubulin antibody
was obtained from Abcam Inc. (Cambridge, MA), and the Hrs
antibody was procured from Alexis Biochemicals/Enzo Life
Sciences (Farmingdale, NY). SRC inhibitor, SU6656, (Calbio-
chem) was used at 2mM.
Cell culture and stable isotope labeling with amino acids
in culture (SILAC)
CA-CSF-1R and CA-CSF-1R Y561F MCF-10A cells were
generated using pMSCV human CSF-1R L301S/Y969F provided
by O. Witte (University of California, Los Angeles, CA). The
Y561F mutant receptor was generated previously by Carolyn
Wrobel [8]. MCF10A cells were grown in a DMEM/F12 based
medium as described previously [64] supplemented with dialyzed
horse serum and either ‘‘light’’ or ‘‘heavy’’ arginine and lysisne.
Cells were labeled over the course of five passages in the labeling
medium prior to analysis. Prior to lysis, cells were cultured
overnight in MCF-10A growth medium supplemented with
reduced (2%) serum and deficient for EGF. Cells were lysed
(9M urea, 20mM HEPES pH 8.0, 2.5mM sodium pyrophospho-
ate, 1mM beta glycerophosphate, and 1mM sodium vanadate).
The lysates were sonicated and cleared by centrifugation in
preparation for protease digestion, phophotyrosine immunopre-
cipitation and tandem liquid chromatography mass spectrometry.
Phosphopeptide immunoprecipitation
Phosphopeptides were prepared using PhosphoScanH Kit (Cell
Signaling Technology).
Analysis by LC-MS/MS Mass Spectrometry
Peptides in the immunoprecipitation eluate (40 ml) were concen-
trated and separated from eluted antibody using Stop and Go
extraction tips (StageTips) [65]. Peptides were eluted from the
microcolumns with 1 ml of 60% MeCN, 0.1% TFA into 7.6 mlo f
0.4% acetic acid/0.005% heptafluorobutyric acid (HFBA). The
sample was loaded onto a 10 cm675 mm PicoFrit capillary column
(New Objective) packed with Magic C18 AQ reversed-phase resin
(Michrom Bioresources) using a Famos autosampler with an inert
sample injection valve (Dionex). The column was developed with a
45-min linear gradient of acetonitrile in 0.4% acetic acid, 0.005%
HFBA delivered at 280 nl/min (Ultimate, Dionex). Tandem mass
spectra were collected in a data-dependent manner with an LTQ ion
trap mass spectrometer (ThermoFinnigan), using a top-ten method, a
dynamic exclusion repeat count of 1, and a repeat duration of 10 sec.
TurboSequest (ThermoFinnigan) searches were done against the
NCBI human database released on August 24, 2004 (containing
27,175 proteins) allowing for tyrosine phosphorylation (Y+80) and
oxidized methionine (M+16) as dynamic modifications. Sequence
assignments were accepted based on the score-filtering criteria we
described previously (Rush et al., 2005), except assignments that had
the score characteristics of false-positive assignments, determined by
searching against a database of reversed protein sequences [66] were
not accepted.
To guide our assignment of the threshold for significant fold
changes phosphorylation, we first graphed the distribution of the non-
phosphorylated peptides present in the immunoprecipitated samples
and determined the mean of the quantitative fold change values. We
assumed data normality based on these distributions; therefore, fold
change values greater than two deviations from the mean are
considered 95% likely to represent significant differences in tyrosine
phosphorylation. Each comparison had a different mean value for the
non-phosphopeptide distribution; however, the same statistical
threshold was applied to both comparisons. For the CA-CSF-1R/
parental MCF-10A comparison, fold change ratios .1.94 were
defined as an upregulation in the levels of tyrosine phosphorylation,
ratios 0.64–1.94 as unchanged, and ratios ,0.64 as a downregulation
of tyrosine phosphorylation. For the CA-CSF-1R/CA-CSF-1R
Y561F comparison, fold change ratios .1.55 were defined as an
upregulation in the levels of tyrosine phosphorylation, ratios 0.63–1.55
as unchanged, and ratios ,0.63 as a downregulation of tyrosine
phosphorylation. All of the detected phosphopeptides were classified
for CSF-1R and SRC regulation on the basis of the calculated relative
fold differences (Table S3).
Immunoprecipitation and Western blot analysis
Cells were lysed in RIPA lysis buffer supplemented with protease
inhibitors and phosphatase inhibitors. Lysates were run on an SDS
10% polyacrylamide gel and transferred onto PVDF membranes
(Millipore, Bedford, MA), and immunoblots were visualized with an
enhanced chemiluminescence kit (Perkin Elmer, Boston, MA).
Phosphorylation Motif Analysis Using Motif-X
The Motif-X algorithm [36] was used to extract significantly
enriched phosphorylation motifs from the phosphopeptide data
set. The identified peptides were centered at the phosphorylated
amino acid and aligned by the algorithm using the human MS
proteome. The probability threshold was set to P,10
24, and the
occurrence threshold was set to a minimum of four peptides.
Biological process enrichment analysis
Proteins identified from the PhosphoScanH analysis were assessed
for enrichment of Gene Ontology and GeneGOH categories using
RTK-Induced SRC substrates
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analysis computes the probability that a set of genes that are
annotated within a specific category would occur by chance and the
results are given in the form of p-values. The enrichment score
provided on bar graphs is computed as 2log(p-value).
Comparative Bioinformatics Analysis
Phosphorylated proteins from the CSF-1R/SRC PhosphoS-
canH analysis were compared to published mass spectrometry
datasets using BioConductor/R (http://www.bioconductor.org/).
SwissProt identifiers from the CSF-1R study were mapped to
human and mouse Entrez Gene Identifiers and merged to Entrez
Gene Identifiers mapped identifiers provided in published studies.
Networks showing the degree of overlap were generated in
Cytoscape using the Cerebral Plug-in. Overlap with published
tumor data sets was performed with a custom Perl script that
identifies overlapping peptides on the basis of peptide sequence.
Correlation p-values were calculated using the right-sided Fisher’s
exact test. To determine whether the phosphorylated proteins
from the CSF-1R/SRC PhosphoScanH analysis have been
previously linked to CSF-1R signaling, a comprehensive CSF-1R
protein interaction network was generated using the Grow Tool in
Ingenuity Pathways Analysis (IngenuityH Systems, www.ingenuity.
com). The genes from this network were cross-referenced to the
proteins from the PhosphoScanH analysis.
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